Critical appraisal of the inclusion criteria in: "Anticoagulant therapy in adult with COVID-19: a systematic review and meta-analysis of randomized controlled trial" for non-severe patients.
作者信息
de Mello Gonzaga Yung Bruno, Mauad Vitor Augusto Queiroz
机构信息
Department of Hematology, Brazilian National Cancer Institute, Rio de Janeiro, Brazil.
Department of Hematology, Group Oncoclínicas, Rio de Janeiro, Brazil.
出版信息
J Thorac Dis. 2025 Apr 30;17(4):2744-2746. doi: 10.21037/jtd-2025-21. Epub 2025 Apr 28.
Abstract
摘要
相似文献
1
Critical appraisal of the inclusion criteria in: "Anticoagulant therapy in adult with COVID-19: a systematic review and meta-analysis of randomized controlled trial" for non-severe patients.
J Thorac Dis. 2025 Apr 30;17(4):2744-2746. doi: 10.21037/jtd-2025-21. Epub 2025 Apr 28.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Anticoagulant therapy in adult with COVID-19: a systematic review and meta-analysis of randomized controlled trial.
J Thorac Dis. 2024 Oct 31;16(10):6391-6405. doi: 10.21037/jtd-24-744. Epub 2024 Oct 17.
4
Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial.
Trials. 2020 Aug 17;21(1):724. doi: 10.1186/s13063-020-04645-z.
5
Antiplatelet/anticoagulant agents for preventing thrombosis events in patients with severe COVID-19: A protocol for systematic review and meta-analysis.
Medicine (Baltimore). 2020 Aug 7;99(32):e21380. doi: 10.1097/MD.0000000000021380.
6
Choosing immunomodulating therapies for the treatment of COVID-19: recommendations based on placebo-controlled trial evidence.
Clin Microbiol Infect. 2024 May;30(5):611-618. doi: 10.1016/j.cmi.2023.12.028. Epub 2024 Jan 3.
7
Benefits of melatonin on mortality in severe-to-critical COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.
Clinics (Sao Paulo). 2025 Apr 4;80:100638. doi: 10.1016/j.clinsp.2025.100638. eCollection 2025.
8
Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Trials. 2020 Oct 20;21(1):866. doi: 10.1186/s13063-020-04774-5.
9
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
Trials. 2020 Nov 24;21(1):965. doi: 10.1186/s13063-020-04813-1.
10
Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.
Trials. 2020 Jun 26;21(1):574. doi: 10.1186/s13063-020-04475-z.
本文引用的文献
1
Anticoagulant therapy in adult with COVID-19: a systematic review and meta-analysis of randomized controlled trial.
J Thorac Dis. 2024 Oct 31;16(10):6391-6405. doi: 10.21037/jtd-24-744. Epub 2024 Oct 17.
2
Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot study.
Pulm Pharmacol Ther. 2023 Jun;80:102212. doi: 10.1016/j.pupt.2023.102212. Epub 2023 Mar 27.
3
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial.
Lancet Haematol. 2022 Aug;9(8):e594-e604. doi: 10.1016/S2352-3026(22)00173-9. Epub 2022 Jun 30.
4
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Lancet Haematol. 2022 Aug;9(8):e585-e593. doi: 10.1016/S2352-3026(22)00175-2. Epub 2022 Jun 30.
5
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.
Lancet. 2022 Jan 1;399(10319):50-59. doi: 10.1016/S0140-6736(21)02392-8. Epub 2021 Dec 15.
6
Randomized Study of Rivaroxaban vs Placebo on Disease Progression and Symptoms Resolution in High-Risk Adults With Mild Coronavirus Disease 2019.
Clin Infect Dis. 2022 Aug 24;75(1):e473-e481. doi: 10.1093/cid/ciab813.
7
A minimal common outcome measure set for COVID-19 clinical research.
Lancet Infect Dis. 2020 Aug;20(8):e192-e197. doi: 10.1016/S1473-3099(20)30483-7. Epub 2020 Jun 12.
Zotero 插件